FATE
Companies
NASDAQ
Fate Therapeutics Inc.
Health Care
$1.19
-$0.45 (-27.27%)
Price Chart
Overview
About FATE
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Market Cap
$418.9M
Volume
2.4M
Avg. Volume
2.6M
P/E Ratio
-0.63690484
Dividend Yield
0.00%
Employees
331.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.32
High Correlation
Volatility
High (0.97)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, FATE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$418.9M
Volume2.4M
P/E Ratio-0.64
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 11, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025